Hello everyone,
For those who want additional details regarding the ENDEAVOR trial results reported above, we've just published an extended news article on the topic. Here's the link:
"High-Dose Kyprolis Extends Progression-Free Survival Versus Velcade In Head-To-Head Relapsed Myeloma Trial," The Myeloma Beacon, March 3, 2015.
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
